MIRA NASDAQ
Miami, FL 33131
US
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Whalen Matthew Pratt | A-Award | 50,000 | $0.94 | 2026-06-12 |
| Del Giudice Matthew | A-Award | 50,000 | $0.94 | 2026-06-12 |
| MacPherson Edward Cl | A-Award | 50,000 | $0.94 | 2026-06-12 |
| Shekhat Denil Nanji | A-Award | 50,000 | $0.94 | 2026-06-12 |
| Mushak Andriy | 0 | — | 2026-06-02 |